135 related articles for article (PubMed ID: 15753355)
1. Circumventing multidrug resistance in cancer by beta-galactoside binding protein, an antiproliferative cytokine.
Ravatn R; Wells V; Nelson L; Vettori D; Mallucci L; Chin KV
Cancer Res; 2005 Mar; 65(5):1631-4. PubMed ID: 15753355
[TBL] [Abstract][Full Text] [Related]
2. The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples.
Di Nicolantonio F; Knight LA; Whitehouse PA; Mercer SJ; Sharma S; Charlton PA; Norris D; Cree IA
Mol Cancer Ther; 2004 Dec; 3(12):1631-7. PubMed ID: 15634657
[TBL] [Abstract][Full Text] [Related]
3. Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
Wells V; Mallucci L
Breast Cancer Res; 2009; 11(1):R2. PubMed ID: 19133120
[TBL] [Abstract][Full Text] [Related]
4. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
Hasegawa S; Abe T; Naito S; Kotoh S; Kumazawa J; Hipfner DR; Deeley RG; Cole SP; Kuwano M
Br J Cancer; 1995 May; 71(5):907-13. PubMed ID: 7734314
[TBL] [Abstract][Full Text] [Related]
5. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
Kim WJ; Kakehi Y; Yoshida O
Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189
[TBL] [Abstract][Full Text] [Related]
6. Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphoma.
Dalton WS
Hematol Oncol Clin North Am; 1997 Oct; 11(5):975-86. PubMed ID: 9336726
[TBL] [Abstract][Full Text] [Related]
7. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
[TBL] [Abstract][Full Text] [Related]
8. Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II.
Xue X; Qu XJ; Gao ZH; Sun CC; Liu HP; Zhao CR; Cheng YN; Lou HX
Invest New Drugs; 2012 Feb; 30(1):212-22. PubMed ID: 20924640
[TBL] [Abstract][Full Text] [Related]
9. Potential role of the antiproliferative cytokine beta-galactoside binding protein in cancer therapy.
Mallucci L; Wells V
Curr Opin Investig Drugs; 2005 Dec; 6(12):1228-33. PubMed ID: 16370387
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors.
Tews DS; Nissen A; Külgen C; Gaumann AK
J Neurooncol; 2000 Dec; 50(3):227-37. PubMed ID: 11263502
[TBL] [Abstract][Full Text] [Related]
11. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
Eijdems EW; Zaman GJ; de Haas M; Versantvoort CH; Flens MJ; Scheper RJ; Kamst E; Borst P; Baas F
Br J Cancer; 1995 Aug; 72(2):298-306. PubMed ID: 7640209
[TBL] [Abstract][Full Text] [Related]
12. Expression of topoisomerase II, bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide.
Herzog CE; Zwelling LA; McWatters A; Kleinerman ES
Clin Cancer Res; 1995 Nov; 1(11):1391-7. PubMed ID: 9815936
[TBL] [Abstract][Full Text] [Related]
13. Cancer resistance to type II topoisomerase inhibitors.
Pilati P; Nitti D; Mocellin S
Curr Med Chem; 2012; 19(23):3900-6. PubMed ID: 22788766
[TBL] [Abstract][Full Text] [Related]
14. Killing of Kras-mutant colon cancer cells via Rac-independent actin remodeling by the βGBP cytokine, a physiological PI3K inhibitor therapeutically effective in vivo.
Mallucci L; Shi DY; Davies D; Jordan P; Nicol A; Lotti L; Mariani-Costantini R; Verginelli F; Wells V; Zicha D
Mol Cancer Ther; 2012 Sep; 11(9):1884-93. PubMed ID: 22752425
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.
Withoff S; de Vries EG; Keith WN; Nienhuis EF; van der Graaf WT; Uges DR; Mulder NH
Br J Cancer; 1996 Dec; 74(12):1869-76. PubMed ID: 8980384
[TBL] [Abstract][Full Text] [Related]
17. Emergence of different mechanisms of resistance in the evolution of multidrug resistance in murine erythroleukemia cell lines.
Modrak DE; Draper MP; Levy SB
Biochem Pharmacol; 1997 Dec; 54(12):1297-306. PubMed ID: 9393672
[TBL] [Abstract][Full Text] [Related]
18. Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
Naito S; Hasegawa S; Yokomizo A; Koga H; Kotoh S; Kuwano M; Kumazawa J
Jpn J Cancer Res; 1995 Nov; 86(11):1112-8. PubMed ID: 8567404
[TBL] [Abstract][Full Text] [Related]
19. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)-resistant cell lines.
Aoyagi Y; Kobunai T; Utsugi T; Wierzba K; Yamada Y
Jpn J Cancer Res; 2000 May; 91(5):543-50. PubMed ID: 10835500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
